Anteris Technologies (ASX:AVR) has welcomed further data from the DurAVR first-in-human study and US early feasibility study.
The company said the data substantiates the “paradigm-shifting” blood flow results reported to date with the DurAVR valve. The valve is a new class of biomimetic transcatheter heart valve designed to restore normal blood flow in aortic stenosis. This is a serious, life-threatening heart condition that occurs when there is a narrowing of the aortic valve.
The latest data includes 30-day results for all 28 patients treated in the study and 30-day results for all 15 patients treated in the early feasibility study.
The company said the data builds on the positive clinical results reported to date which demonstrate this new class of biomimetic valve outperforms the market leader, returning patients to a near normal blood flow state.
